Novartis acquires Boston immunotherapy startup
By Hannah Green Novartis is once again shelling out millions to buy a subsidiary of Boston-based IFM Therapeutics. Novartis (NYSE: NVS) said on Wednesday it is acquiring all of the outstanding capital stock of IFM Due, a subsidiary company of IFM. Novartis is paying IFM $90 million upfront for this acquisition, and IFM will also be […]